RecruitingPhase 2NCT04547439

Sleep, Diabetic Retinopathy and Melatonin

Sleep and Circadian Regulation in Diabetic Retinopathy: The Role of Intrinsically Photosensitive Retinal Ganglion Cells and Melatonin Supplementation


Sponsor

University of Illinois at Chicago

Enrollment

42 participants

Start Date

Feb 3, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

This study explores the use of melatonin in patients with diabetic retinopathy


Eligibility

Min Age: 40 YearsMax Age: 65 Years

Inclusion Criteria3

  • Type 2 diabetes (clinically diagnosed, taking anti-diabetes medications or history of elevated A1C≥6.5%)
  • -65 years of age
  • Diabetic retinopathy of at least moderate degree

Exclusion Criteria21

  • use of melatonin
  • antidepressants or antipsychotics
  • illicit drug use
  • night shift work or travel beyond 2 time zones in the month before enrollment
  • end stage renal disease requiring renal replacement therapy
  • history of stroke or transient ischemic attacks
  • history of dementia or memory impairment
  • uncontrolled congestive heart failure or recent hospitalization for cardiac condition (6 months)
  • chronic obstructive pulmonary disease requiring oxygen
  • severe chronic liver disease such as cirrhosis
  • ongoing treatment for major medical problems such as cancer
  • history of severe hypoglycemia defined as hypoglycemic episodes requiring assistance from others within the past six months.
  • Significant depressive symptoms
  • untreated severe OSA (AHI≥ 30 events/hour),
  • uncontrolled hypertension (blood pressure ≥ 160/100 mmHg),
  • uncontrolled diabetes (A1C ≥ 11%),
  • abnormal TSH
  • abnormal liver function (AST or ALT>3x upper limits of normal
  • use of sedatives and hypnotics.
  • clinically significant epiretinal membranes, clinically significant lens opacities, or cystoid macular edema, iris neovascularization, iris atrophy, or an asymmetrically shaped pupil, nuclear sclerotic, posterior subcapsular, or cortical lens opacities greater than 2+, a history of pan-retinal photocoagulation.
  • hemoglobin <11.5 g/dL in women and <13.5 g/dL in men.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMelatonin

Melatonin 3 mg will be taken nightly for 8 weeks

OTHERPlacebo

Placebo will be given nightly for 8 weeks


Locations(1)

University of Illinois at Chicago

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04547439


Related Trials